Alchalby, Haefaa

et al.

Schroyens, Wilfried

Stuebig, Thomas

Zabelina, Tatjana

Abstract: Transformed acute myeloid leukemia in myelofibrosis results in a median survival of less than 5 months. We identified 46 of 1048 myelofibrosis patients in the European Group for Blood and Marrow Transplantation registry who received allogeneic stem cell transplantation for acute leukemia evolving from myelofibrosis. The cumulative incidence of treatment-related mortality at 1 year was 28% (95% confidence interval, 14 to 42) and of relapse at 3 years was 47% (95% confidence interval, 31 to 63). The 3-year progression-free (PFS) and overall survival (OS) rates were 26% and 33%, respectively. The only significant factor for survival was complete remission versus no complete remission before transplantation (69% versus 22%, P = .008); however, complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myelofibrosis patients transformed to leukemia. (C) 2014 American Society for Blood and Marrow Transplantation

Institutional Repository Universiteit Antwerpen

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation : a study from the myeloproliferative neoplasm subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation : a study from the myeloproliferative neoplasm subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation

Abstract

Similar works

Full text

Available Versions

Institutional Repository Universiteit Antwerpen